C. Jimmy Lin, MD, PhD, MHS is the Chief Scientific Officer (CSO), Oncology at Natera and a TED Fellow. He comes from a long history as a pioneer in cancer genomics. Most recently, he led the clinical genomics program at the National Cancer Institute (NCI) at the National Institutes of Health (NIH). Previously, at Johns Hopkins and Washington University in St. Louis, Lin was part of one of the first clinical genomics labs in academia and led the computational analyses of the first ever exome sequencing studies in cancer, including breast, colorectal, pancreatic, glioblastoma, medulloblastoma and melanoma.
Lin has published in top academic journals, such as Science, Nature and Cell, and he has been an expert in national and international media outlets, such as New York Times, Forbes, Bloomberg Businessweek, The Washington Post, and the Financial Times.
A new DNA technology that analyzes human blood samples has been shown to catch the disease four months earlier than traditional methods. Cancer researcher Jimmy Lin explains how it works.
Continue readingJimmy Lin shares how patients suffering from a rare genetic disorder can find the equally rare researcher who can help.
Continue readingToday is World Rare Disease Day – an event launched in 2008 to galvanize public awareness and research momentum for rare diseases. In the United States, a disease is considered rare if it affects fewer than 200,000 people. Yet there are more than 7,000 known rare diseases. This ratio means that there’s little funding for […]
Continue reading